8-K: Achieve Life Sciences Secures Up to $124.2 Million in Financing to Advance Smoking Cessation Drug

Achieve Life Sciences has announced a financing deal that could provide up to $124.2 million to support the development of its smoking cessation drug, cytisinicline.

Summary

• Achieve Life Sciences has entered into a securities purchase agreement to raise up to $124.2 million through a registered direct offering and a concurrent private placement.
• The initial upfront funding is $60 million, with the potential for an additional $64.2 million upon the exercise of milestone-driven warrants.
• The registered direct offering involves the sale of 13,086,151 shares of common stock at $4.585 per share.
• The concurrent private placement includes warrants to purchase up to 13,086,151 shares of common stock at an exercise price of $4.906 per share, or pre-funded warrants at $4.905 per share.
• The warrants are exercisable immediately and expire three and a half years after issuance or 30 days after public disclosure of the FDA's acceptance of the NDA for cytisinicline.
• The company estimates net proceeds from the offering to be approximately $56.2 million, after deducting fees and expenses.
• If all private placement warrants are exercised, the company would receive an additional $64.2 million in gross proceeds.
• The company intends to use the net proceeds to fund clinical development of cytisinicline through NDA submission, expected in the first half of 2025, including the ORCA-OL clinical trial.
• The company expects that the net proceeds from the offering and warrant exercises will be sufficient to fund the development of cytisinicline into 2026 and through potential FDA approval.
• The company also intends to use a portion of the net proceeds for potential acquisitions or investments in technologies, intellectual property, or businesses that complement its business.

Sentiment

Score: 7

Explanation: The document is generally positive, highlighting a significant capital raise to fund the company's operations and clinical trials. However, there are some risks and uncertainties associated with the offering, such as the potential for dilution and the contingency of warrant exercises.

Positives

• The financing provides significant capital to advance cytisinicline through the NDA submission process.
• The potential for additional funding through warrant exercises could extend the runway for development through potential FDA approval.
• The participation of healthcare-dedicated investors and strategic partners indicates confidence in the company's prospects.
• The company has a clear plan for the use of proceeds, focusing on clinical development and potential acquisitions.
• The company expects the net proceeds from the offering and warrant exercises will be sufficient to fund its development of cytisinicline into 2026 and through potential FDA approval.

Negatives

• The offering involves the issuance of a significant number of new shares, which could dilute existing shareholders.
• The additional $64.2 million in funding is contingent on the exercise of warrants, which is not guaranteed.
• The company's preliminary cash balance as of December 31, 2023, was approximately $15.6 million, which may be considered low for a company in late-stage clinical development.
• The company's audited financial statements for the year ended December 31, 2023, are not yet available, which introduces some uncertainty.

Risks

• The company's financial results for the year ended December 31, 2023, are preliminary and subject to change.
• The company's ability to achieve NDA submission in the first half of 2025 is subject to clinical trial success and regulatory approval.
• The company's ability to secure additional funding through warrant exercises is not guaranteed.
• The company's stock price could be negatively impacted by the issuance of new shares.
• The company's ability to successfully commercialize cytisinicline is subject to regulatory approval and market acceptance.

Future Outlook

The company expects that the net proceeds from the offering and warrant exercises will be sufficient to fund the development of cytisinicline into 2026 and through potential FDA approval. The company also intends to use a portion of the net proceeds for potential acquisitions or investments in technologies, intellectual property, or businesses that complement its business.

Management Comments

• The company intends to use the proceeds from the offering to fund clinical development of cytisinicline through NDA submission, expected in 1H 2025, including the ORCA-OL clinical trial, to fund other cytisinicline related research and clinical development activities and for working capital and general corporate purposes.
• The company expects that the net proceeds from the registered direct offering and concurrent private placement, assuming the exercise of all of the milestone-driven warrants, will be sufficient to fund its development of cytisinicline into 2026 and through potential FDA approval.

Industry Context

This announcement comes as the pharmaceutical industry continues to focus on developing new treatments for smoking cessation and nicotine dependence. The company's cytisinicline is a plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor, which is a novel approach to treating nicotine addiction.

Comparison to Industry Standards

• The financing structure, combining a registered direct offering with a concurrent private placement of warrants, is a common approach for biotech companies seeking to raise capital.
• The company's focus on a plant-based alkaloid for smoking cessation aligns with the industry's trend towards exploring novel therapeutic approaches.
• The company's timeline for NDA submission in the first half of 2025 is consistent with the development timelines of other late-stage pharmaceutical companies.
• The company's estimated net proceeds of $56.2 million from the offering is a significant amount of capital for a company of its size, but is not unusual for a company in late-stage clinical development.
• The potential additional $64.2 million from warrant exercises is a significant amount of capital, but is contingent on the exercise of warrants, which is not guaranteed.

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of new shares.
• Employees may benefit from the company's increased financial stability and ability to fund its operations.
• Customers may benefit from the company's continued development of cytisinicline, a potential new treatment for smoking cessation.
• Creditors may benefit from the company's improved financial position.

Next Steps

• The company will complete the closing of the registered direct offering and concurrent private placement, expected on or about March 4, 2024.
• The company will use the net proceeds to fund clinical development of cytisinicline through NDA submission, expected in the first half of 2025.
• The company will file a registration statement for the resale of the Common Warrant Shares and Milestone Pre-Funded Warrant Shares.

Key Dates

Keywords

cytisinicline, smoking cessation, nicotine dependence, registered direct offering, private placement, warrants, NDA submission, clinical development, FDA approval, ORCA-OL trial